Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-03-14 4:19 pm Purchase | 2023-03-09 | 13D | Theseus Pharmaceuticals, Inc. THRX | ORBIMED ADVISORS LLC | 17,233,668 39.600% | 395,000 (+2.35%) | Filing History |
| 2023-02-28 5:09 pm Sale | 2023-02-16 | 13D | Fusion Pharmaceuticals Inc. FUSN | ORBIMED ADVISORS LLC | 2,930,670 4.700% | -67,311 (-2.25%) | Filing History |
| 2023-02-28 4:00 pm Purchase | 2023-02-23 | 13D | Enliven Therapeutics, Inc. ELVN | ORBIMED ADVISORS LLC | 8,949,339 21.800% | 8,949,339 (New Position) | Filing History |
| 2023-02-23 3:23 pm Purchase | 2023-02-17 | 13D | Kinnate Biopharma Inc. KNTE | ORBIMED ADVISORS LLC | 4,693,629 10.600% | 1,295,700 (+38.13%) | Filing History |
| 2023-02-14 5:24 pm Purchase | 2022-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | ORBIMED ADVISORS LLC | 344,288 8.200% | 283,077 (+462.46%) | Filing History |
| 2023-02-14 5:20 pm Sale | 2022-12-31 | 13G | VistaGen Therapeutics, Inc. VTGN | ORBIMED ADVISORS LLC | 0 0.000% | -350,641 (Position Closed) | Filing History |
| 2023-02-14 5:16 pm Purchase | 2022-12-31 | 13G | Verastem, Inc. VSTM | ORBIMED ADVISORS LLC | 1,375,270 7.900% | 1,375,270 (New Position) | Filing History |
| 2023-02-14 5:12 pm Purchase | 2022-12-31 | 13G | VectivBio Holding AG VECT | ORBIMED ADVISORS LLC | 6,713,561 10.700% | 1,810,057 (+36.91%) | Filing History |
| 2023-02-14 5:07 pm Sale | 2022-12-31 | 13G | Theravance Biopharma, Inc. TBPH | ORBIMED ADVISORS LLC | 0 0.000% | -5,456,780 (Position Closed) | Filing History |
| 2023-02-14 5:04 pm Sale | 2022-12-31 | 13G | Sonendo, Inc. SONX | ORBIMED ADVISORS LLC | 0 0.000% | -49 (Position Closed) | Filing History |
| 2023-02-14 4:59 pm Purchase | 2022-12-31 | 13G | SI-BONE, Inc. SIBN | ORBIMED ADVISORS LLC | 3,201,100 9.300% | 3,201,100 (New Position) | Filing History |
| 2023-02-14 4:55 pm Sale | 2022-12-31 | 13G | RxSight, Inc. RXST | ORBIMED ADVISORS LLC | 923,733 3.300% | -138,767 (-13.06%) | Filing History |
| 2023-02-14 4:52 pm Unchanged | 2022-12-31 | 13G | Protara Therapeutics, Inc. TARA | ORBIMED ADVISORS LLC | 671,741 6.000% | 0 (Unchanged) | Filing History |
| 2023-02-14 4:48 pm Unchanged | 2022-12-31 | 13G | NeuroPace, Inc. NPCE | ORBIMED ADVISORS LLC | 4,012,281 16.100% | 0 (Unchanged) | Filing History |
| 2023-02-14 4:43 pm Purchase | 2022-12-31 | 13G | Mersana Therapeutics, Inc. MRSN | ORBIMED ADVISORS LLC | 283,313 7.100% | 283,313 (New Position) | Filing History |
| 2023-02-14 4:40 pm Purchase | 2022-12-31 | 13G | Mereo BioPharma Group plc MREO | ORBIMED ADVISORS LLC | 10,378,591 5.920% | 4,315,246 (+71.17%) | Filing History |
| 2023-02-14 4:37 pm Sale | 2022-12-31 | 13G | MeiraGTx Holdings plc MGTX | ORBIMED ADVISORS LLC | 0 0.000% | -3,593,966 (Position Closed) | Filing History |
| 2023-02-14 4:32 pm Purchase | 2022-12-31 | 13G | Kezar Life Sciences, Inc. KZR | ORBIMED ADVISORS LLC | 349,512 5.100% | 349,512 (New Position) | Filing History |
| 2023-02-14 4:30 pm Sale | 2022-12-31 | 13G | Jounce Therapeutics, Inc. JNCE | ORBIMED ADVISORS LLC | 0 0.000% | -2,200,200 (Position Closed) | Filing History |
| 2023-02-14 4:25 pm Sale | 2022-12-31 | 13G | Harpoon Therapeutics, Inc. HARP | ORBIMED ADVISORS LLC | 80,421 2.400% | -86,369 (-51.78%) | Filing History |